$2.09 -0.02 (-0.95%)
12/4/2009 11:51 AM

Pharmacyclics, Inc. (PCYC)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases.

Current Price $2.09 Mkt Cap $104.65M
Open $2.13 P/E Ratio 0.00
Prev. Close $2.11 Div. (Yield) N/A (N/A)
Daily Range $2.09 - $2.31 Volume 52,804
52-Wk Range $0.57 - $2.41 Avg. Daily Vol. 37,000

PCYC News and Commentary

Related News and Articles

Caps

How do you think PCYC will perform vs the S&P 500?

Add Stock to Watchlist

All Members

26 Outperform
1 Underperform
 

All-Star Members

5 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top PCYC Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

darkflame (96.74)
Submitted July 03, 2007

... the insider buying in PHARMACYCLICS, INC is not real insider, but a benefial owner, which happens to be a company called Robert W Duggan, check http://www.dugganassociates.com

Now...the problem is, most of these money management… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

PCYC VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from members about PCYC.

Recs

0
Member Avatar Displacement (87.11) Submitted: 9/28/2009 5:31:22 PM : Underperform Start Price: $1.99 PCYC Score: -6.50

This swine flu mover has turned the corner and lost its momentum. It's just not worth $2.

Recs

0
Member Avatar darkflame (96.74) Submitted: 7/3/2007 10:20:51 AM : Outperform Start Price: $5.40 PCYC Score: -44.28

... the insider buying in PHARMACYCLICS, INC is not real insider, but a benefial owner, which happens to be a company called Robert W Duggan, check http://www.dugganassociates.com

Now...the problem is, most of these money management companies don't beat the markets, specially the ones focusing in small stocks. I checked what they said in the page and they "predict future prices"... well, and I say, they can do that because nobody else can.
Robbert W Duggan sells bad funds and invest in stocks in a way that will yield random results.

I checked their fee structure...a very tipical money scam, 20% of the profits!!! Likely they will take high risks to have high profits, if all the money is lost they won't have to pay 20% of what you lost.... so, one more case of unbalanced probabilities relating to rewards.

I regret having picked this company, I think it's time to read more about the company, then lick my wounds and close it.

Recs

0
Member Avatar biotiempo (53.05) Submitted: 4/4/2007 10:18:26 AM : Outperform Start Price: $4.91 PCYC Score: -36.59

After the Dendreon panel recommendation, Pharmacyclics made a filing with the FDA that among other things seeks a review of Xcytrin by an outside panel of experts. This coupled with lung cancer advocacy group involvement increases the chances of a favorable outcome regarding FDA approval.

Leaderboard

Find the members with the highest scoring picks in PCYC.

Score Leader

drugncover

drugncover (34.28) Score: +37.74

The Score Leader is the member with the highest score across all their picks in PCYC.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score Commentary
dennisdee5 < 20 12/4/2009 Outperform 5Y $2.13 +3.57% -0.62% +4.19
Displacement 87.11 9/29/2009 Underperform 1Y $1.99 +10.85% +4.36% -6.50 1 Comment
shpacr 98.93 2/1/2007 Outperform NS $4.85 -54.52% -18.23% -36.29
biotiempo 53.05 2/5/2007 Outperform 1Y $4.91 -55.07% -18.48% -36.59 1 Comment
hibetals 98.10 2/20/2007 Outperform NS $5.01 -55.97% -18.95% -37.02
23USMC 52.06 12/29/2006 Outperform 1Y $4.91 -55.07% -16.91% -38.16
WindsAloft 34.26 1/3/2007 Outperform 5Y $5.00 -55.88% -17.59% -38.29
hixey 74.87 12/22/2006 Outperform 5Y $4.95 -55.43% -16.38% -39.05
GatorFan1990 < 20 1/22/2007 Outperform 1Y $5.10 -56.75% -17.54% -39.21 2 Comments
erictao < 20 12/22/2006 Outperform 3M $4.98 -55.70% -16.42% -39.28 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackTWeisel < 20 11/20/2006 Outperform NS $6.12 -47.88% +4.05% -51.93 2/21/2007 @ $3.19

Featured Broker Partners